Literature DB >> 33656710

Neurological Complications of the COVID-19 Pandemic: What Have We Got So Far?

Isabelle Pastor Bandeira1, Marco Antônio Machado Schlindwein1, Leticia Caroline Breis1, Jean Pierre Schatzmann Peron2,3,4, Marcus Vinícius Magno Gonçalves5.   

Abstract

The recently emerged coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of COVID-19, is the newest threat to human health. It has already infected more than 54.5 million people worldwide, currently leading to more than 1.3 million deaths. Although it causes a mild flu-like disease in most patients, lethality may increase to more than 20% in elderly subjects, especially in those with comorbidities, like hypertension, diabetes, or lung and cardiac disease, and the mechanisms are still elusive. Common symptoms at the onset of illness are fever, cough, myalgia or fatigue, headache, and diarrhea or constipation. Interestingly, respiratory viruses have also placed themselves as relevant agents for central nervous system (CNS) pathologies. Conversely, SARS-CoV-2 has already been detected in the cerebrospinal fluid. Here, we discuss several clinical features related to CNS infection during COVID-19. Patients may progress from headaches and migraines to encephalitis, stroke, and seizures with leptomeningitis. However, the pathway used by the virus to reach the brain is still unknown. It may infect the olfactory bulb by retrograde neuronal transportation from olfactory epithelium, or it could be transported by the blood. Either way, neurological complications of COVID-19 add greatly to the complex pathophysiology of the disease. Neurological signs and symptoms must alert physicians not only to worst outcomes but also to future possible degenerative diseases.

Entities:  

Keywords:  Anosmia; COVID-19; Coronavirus; Neurology; SARS-CoV-2

Year:  2021        PMID: 33656710     DOI: 10.1007/978-3-030-59261-5_2

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

1.  Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study.

Authors:  Harvey Moldofsky; John Patcai
Journal:  BMC Neurol       Date:  2011-03-24       Impact factor: 2.474

Review 2.  Neurologic Alterations Due to Respiratory Virus Infections.

Authors:  Karen Bohmwald; Nicolás M S Gálvez; Mariana Ríos; Alexis M Kalergis
Journal:  Front Cell Neurosci       Date:  2018-10-26       Impact factor: 5.505

3.  Zika virus replicates in adult human brain tissue and impairs synapses and memory in mice.

Authors:  Claudia P Figueiredo; Fernanda G Q Barros-Aragão; Rômulo L S Neris; Paula S Frost; Carolina Soares; Isis N O Souza; Julianna D Zeidler; Daniele C Zamberlan; Virginia L de Sousa; Amanda S Souza; André Luis A Guimarães; Maria Bellio; Jorge Marcondes de Souza; Soniza V Alves-Leon; Gilda A Neves; Heitor A Paula-Neto; Newton G Castro; Fernanda G De Felice; Iranaia Assunção-Miranda; Julia R Clarke; Andrea T Da Poian; Sergio T Ferreira
Journal:  Nat Commun       Date:  2019-09-05       Impact factor: 14.919

4.  Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy.

Authors:  Asia Filatov; Pamraj Sharma; Fawzi Hindi; Patricio S Espinosa
Journal:  Cureus       Date:  2020-03-21

5.  Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues.

Authors:  Meng-Yuan Li; Lin Li; Yue Zhang; Xiao-Sheng Wang
Journal:  Infect Dis Poverty       Date:  2020-04-28       Impact factor: 4.520

6.  Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young.

Authors:  Thomas J Oxley; J Mocco; Shahram Majidi; Christopher P Kellner; Hazem Shoirah; I Paul Singh; Reade A De Leacy; Tomoyoshi Shigematsu; Travis R Ladner; Kurt A Yaeger; Maryna Skliut; Jesse Weinberger; Neha S Dangayach; Joshua B Bederson; Stanley Tuhrim; Johanna T Fifi
Journal:  N Engl J Med       Date:  2020-04-28       Impact factor: 91.245

7.  Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.

Authors:  Tao Chen; Di Wu; Huilong Chen; Weiming Yan; Danlei Yang; Guang Chen; Ke Ma; Dong Xu; Haijing Yu; Hongwu Wang; Tao Wang; Wei Guo; Jia Chen; Chen Ding; Xiaoping Zhang; Jiaquan Huang; Meifang Han; Shusheng Li; Xiaoping Luo; Jianping Zhao; Qin Ning
Journal:  BMJ       Date:  2020-03-26

8.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.